5 results about "Virus type" patented technology

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The present disclosure relates to a recombinant protein comprising a food and mouth disease virus (FMDV) virus like particle (VLP) and a fragment crystallizable region (Fc) of a swine-derived immunoglobulin linked to the surface of the VLP, and a vaccine composition comprising the recombinant protein. The recombinant protein of the present disclosure may form a self-assembling structure including a virus-like particle using a protein derived from a capsid protein of FMDV, which is an antigenic protein, and a swine Fc protein located on the surface of the virus-like particle, and by using a vaccine composition including the recombinant protein, a specific antibody against FMDV may be effectively produced.

The present disclosure provides isolated peptides derived from human T-lymphotropic virus type 1 (HTLV-1), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides methods and systems for identifying immunogenic virus-derived peptides.

Described is a vaccine against porcine reproductive and respiratory syndrome (PRRS) caused by PRRS virus type 1 (PRRSV-1), which comprises an apathogenic live strain of PRRS virus type 2 (PRRSV-2) and a pharmaceutically acceptable vehicle, adjuvant and / or excipient. The vaccine prevents the disease caused by PRRSV-1.

To provide compositions and methods for detecting a viral pathogen in a sample.SOLUTION: The present disclosure relates to amplification primers, hybridization assay probes, compositions containing such primers and probes, and related reagents, kits, and methods that can be used to analyze samples for the presence of influenza A virus, influenza B virus, respiratory syncytial virus type A, and / or respiratory syncytial virus type B target nucleic acids.SELECTED DRAWING: None